MedWatch

FDA rejects schizophrenia drug from Teva

The US health authority has given its thumbs-down for a schizophrenia drug candidate developed by Teva in a collaboration with French biotech firm Medincell.

Danish national Kåre Schultz is chief executive of Teva, which has just received the FDA's thumbs-down for its candidate drug against schizophrenia | Photo: Amir Cohen/Reuters/Ritzau Scanpix

A potentially new treatment for schizophrenia has been sent back to the development phase, the pharmaceutical firm behind the drug, Teva, has announced in a press release on Tuesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs